Diurnal Group PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Diurnal Group PLC
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
New treatments for congenital adrenal hyperplasia and relapsing forms of multiple sclerosis are among five drugs recommended for pan-EU approval this month. In addition, harmonized EU advice has been issued for Celltrion’s monoclonal antibody COVID-19 treatment.
The European Medicines Agency is deciding on the EU marketing application for Chronocort, a life-long treatment for congenital adrenal hyperplasia.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Diurnal Limited